Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)

Palliative imatinib treatment has dramatically improved survival in patients with malignant gastrointestinal stromal tumours, particularly in patients with tumours harbouring activating KIT mutations. To evaluate the effectiveness of adjuvant imatinib after radical surgery, a consecutive series of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Nilsson, B, Sjölund, K, Kindblom, L-G, Meis-Kindblom, J M, Bümming, P, Nilsson, O, Andersson, J, Ahlman, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359924/
https://www.ncbi.nlm.nih.gov/pubmed/17533389
http://dx.doi.org/10.1038/sj.bjc.6603797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359924/
https://www.ncbi.nlm.nih.gov/pubmed/17533389
http://dx.doi.org/10.1038/sj.bjc.6603797

Ejemplares similares